Table 1.
Patient and disease characteristics
| No cGVHD and mild cGVHD (n = 60) | Moderate to severe cGVHD (n = 38) | |
|---|---|---|
| Patient sex | ||
| F/m | 30/30 | 14/24 |
| Donor sex | ||
| F/m | 23/37 | 24/14 |
| Patient age | ||
| < 50 | 15/60 (25%) | 9/38 (24%) |
| ≥ 50 | 45/60 (75%) | 29/38 (76%) |
| Donor age | ||
| < 50 | 33/60 (55%) | 23/38 (60%) |
| ≥ 50 | 27/60 (45%) | 15/38 (40%) |
| Donor/patient transplant | ||
| ♂♂ | 19/60 (32%) | 10/38 (26%) |
| ♂♀ | 18/60 (30%) | 4/38 (10%) |
| ♀♀ | 12/60 (20%) | 10/38 (26%) |
| ♀♂ | 11/60 (18%) | 14/38 (38%) |
| Transfusions | ||
| < 76 | 49/58 (84%) | 34/36 (94%) |
| ≥ 76 | 9/58 (16%) | 2/36 (6%) |
| Recipient HLA antibodies positivea | 6/60 (10%) | 11/38 (29%) |
| CMV positive donor/recipient | 52/60 (87%) | 34/38 (89%) |
| CMV positive donor | 32/60 (53%) | 20/38 (53%) |
| CMV positive recipient | 48/60 (80%) | 24/38 (63%) |
| Risk at diagnosis | ||
| Low risk | 1/60 (2%) | 1/37 (3%) |
| Moderate risk | 28/60 (47%) | 22/37 (59%) |
| Poor risk/very poor risk | 31/60 (51%) | 14/37 (38%) |
| Conditioning | ||
| Flu/TBI | 52/60 (92%) | 31/38 (82%) |
| Other | 8/60 (8%) | 7/38 (18%) |
| Remission prior to transplantation | ||
| Complete remission | 53/60 (88%) | 32/38 (84%) |
| No remission | 5/60 (8%) | 5/38 (13%) |
| Persisting aplasia after chemotherapy | 2/60 (4%) | 1/38 (3%) |
| Type of transplant | ||
| Sibling | 34/60 (57%) | 19/38 (50%) |
| MUD | 26/60 (43%) | 19/38 (50%) |
| HLA match | ||
| 10/10 MUD | 33/60 (55%) | 17/38 (45%) |
| 9/10 MUD | 1/60 (2%) | 2/38 (5%) |
| Sibling | 26/60 (43%) | 19/38 (50%) |
| DPB1 | ||
| Match | 40/60 (66%) | 23/38 (60%) |
| Permissive | 10/60 (17%) | 8/38 (21%) |
| Non-permissive | 10/60 (17%) | 7/38 (19%) |
| GVHD prophylaxis | ||
| CsA/MMF | 56/60 (94%) | 32/38 (8%) |
| Other | 4/60 (7%) | 6/38 (16%) |
| Infused cells | Median (range) | Median (range) |
| CD3+ 106/kg | 246.8 (80.0–573.0) | 303.6 (140.2–642.6) |
| CD19+ 106/kg | 55.6 (12.0–131.3) | 70.4 (18.0–333.5) |
| CD34+ 106/kg | 6.6 (2.2–18.5) | 6.4 (2.6–13.5) |
GVHD graft-versus-host disease, HLA human leukocyte antigen, CMV cytomegalovirus, Flu fludarabine, TBI total body irradiation, MUD matched unrelated donor, CsA cyclosporine, MMF mycophenolate mofetil
aHLA antibodies found prior to transplantation in the serum